AbstractTumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant subtypes based on core gene signatures. However, molecular signaling in glioma stem cells (GSCs) in individual HGG subtypes is poorly characterized. Previously we identified and characterized two mutually exclusive GSC subtypes with distinct activated signaling pathways and biological phenotypes. One GSC subtype presented with a gene signature resembling Proneural (PN) HGG, whereas the other was similar to mesenchymal (Mes) HGG. Classical HGG-derived GSCs were sub-classified as either one of these two subtypes. Differential mRNA expression analysis of PN and Mes GSCs identified 5796 differentially expressed genes, revealing a pronounced correlat...
Glioblastoma (World Health Organization/WHO grade IV) is the most common and most aggressive adult g...
Tumor heterogeneity is a major obstacle for finding effective treatment of G...
Glioblastoma (GBM) is the most common and aggressive form of adult primary brain cancer. Therapeutic...
Tumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant subtypes ba...
AbstractTumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant sub...
International audienceRecent studies have demonstrated a relationship between the expression of stem...
Although tumor-propagating cells can be derived from glioblastomas (GBM) of the proneural and mesenc...
Background: Glioblastoma (GBM), a highly malignant brain tumor, invariably recurs after therapy. Qui...
Glioblastoma multiforme (GBM) is the most common and lethal form of primary brain tumor that mainly ...
Glioblastoma (World Health Organization/WHO grade IV) is the most common and most aggressive adult g...
AbstractGlioblastoma is the most common brain tumor. Median survival in unselected patients is <10 m...
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma m...
Background: Tumor heterogeneity is a major obstacle for finding effective treatment of Glioblastoma ...
Glioblastoma (GBM) is known as an intractable, highly heterogeneous tumor encompassing multiple subc...
SummaryThe Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in gliobla...
Glioblastoma (World Health Organization/WHO grade IV) is the most common and most aggressive adult g...
Tumor heterogeneity is a major obstacle for finding effective treatment of G...
Glioblastoma (GBM) is the most common and aggressive form of adult primary brain cancer. Therapeutic...
Tumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant subtypes ba...
AbstractTumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant sub...
International audienceRecent studies have demonstrated a relationship between the expression of stem...
Although tumor-propagating cells can be derived from glioblastomas (GBM) of the proneural and mesenc...
Background: Glioblastoma (GBM), a highly malignant brain tumor, invariably recurs after therapy. Qui...
Glioblastoma multiforme (GBM) is the most common and lethal form of primary brain tumor that mainly ...
Glioblastoma (World Health Organization/WHO grade IV) is the most common and most aggressive adult g...
AbstractGlioblastoma is the most common brain tumor. Median survival in unselected patients is <10 m...
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma m...
Background: Tumor heterogeneity is a major obstacle for finding effective treatment of Glioblastoma ...
Glioblastoma (GBM) is known as an intractable, highly heterogeneous tumor encompassing multiple subc...
SummaryThe Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in gliobla...
Glioblastoma (World Health Organization/WHO grade IV) is the most common and most aggressive adult g...
Tumor heterogeneity is a major obstacle for finding effective treatment of G...
Glioblastoma (GBM) is the most common and aggressive form of adult primary brain cancer. Therapeutic...